MOORE LINDA V 4
4 · MARRONE BIO INNOVATIONS INC · Filed Jul 14, 2022
Insider Transaction Report
Form 4
MOORE LINDA V
General Counsel
Transactions
- Exercise/Conversion
Restricted Stock Units
2022-07-12−316,153→ 0 total→ Common Stock (316,153 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−259,091→ 0 totalExercise: $0.63Exp: 2032-02-06→ Common Stock (259,091 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−150,000→ 0 totalExercise: $1.65Exp: 2028-05-30→ Common Stock (150,000 underlying) - Award
Common Stock
2022-07-12+316,153→ 450,839 total - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−100,000→ 0 totalExercise: $1.23Exp: 2026-03-01→ Common Stock (100,000 underlying) - Disposition to Issuer
Common Stock
2022-07-12−450,839→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−300,000→ 0 totalExercise: $1.44Exp: 2029-07-16→ Common Stock (300,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2022-07-12−100,000→ 0 totalExercise: $14.61Exp: 2024-03-17→ Common Stock (100,000 underlying)
Footnotes (10)
- [F1]Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
- [F10]This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of March 17, 2014, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 8,800 Ordinary Shares of BIOX for $166.02 per share.
- [F2]The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
- [F3]Disposed of pursuant to the Merger Agreement in exchange for 35,467 BIOX Ordinary Shares having a market value of $9.44 per share on the effective date of the Merger and 4,207 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
- [F4]Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
- [F5]Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
- [F6]This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 111,555 shares and replaced with an option to purchase 9,817 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 5,614 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
- [F7]This option, which provided for vesting 1/3 of the total shares subject to the option on the first anniversary of the vesting commencement date of March 1, 2016, and with respect to 1/36 of the total shares subject to the option monthly thereafter for 24 months, was assumed by BIOX in the Merger and replaced with an option to purchase 8,800 Ordinary Shares of BIOX for $13.98 per share.
- [F8]This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 26,400 Ordinary Shares of BIOX for $16.36 per share.
- [F9]This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 13,200 Ordinary Shares of BIOX for $18.75 per share.